<DOC>
	<DOCNO>NCT00051090</DOCNO>
	<brief_summary>This study evaluate drug telbivudine ( LdT ) treatment hepatitis B virus ( HBV ) HIV infect patient . Patients take telbivudine alone 24 week , add anti-HIV drug 24 week , stop take telbivudine continue anti-HIV drug regimen . To enroll study , patient must take anti-HIV drug take 31 day treatment lamivudine ( 3TC ) , protease inhibitor ( PIs ) , nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) .</brief_summary>
	<brief_title>Treatment Hepatitis B Virus ( HBV ) Before Beginning Anti-HIV Drugs Patients With Both HBV HIV</brief_title>
	<detailed_description>Studies indicate 70 % 80 % HIV infect patient HBV infection 10 % HBV carrier . Lamivudine therapy treatment HBV HIV infect patient limited long-term efficacy due development resistance mutation . Telbivudine thymidine analogue excellent HBV inhibitory activity anti-HIV activity . The primary objective study evaluate safety anti-HBV activity telbivudine alone combination lamivudine-based highly active antiretroviral therapy ( HAART ) regimen patient coinfected HBV HIV . Patients study take telbivudine 24 week . At Week 24 , patient add HAART regimen contain lamivudine efavirenz plus either didanosine abacavir . Patients unable add HAART regimen Week 24 due lab abnormality contraindication allow delay initiation HAART Week 30 . Patients may initiate HAART prior Week 24 deem medically necessary primary HIV care provider . Patients take telbivudine HAART 24 week . At Week 48 , patient discontinue telbivudine continue HAART regimen alone additional 12 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>HIV positive No antiretroviral therapy within 6 month prior study entry Less 31 day cumulative therapy lamivudine , protease inhibitor , nonnucleoside reverse transcriptase inhibitor Willingness delay HAART least Week 24 study Ability procure initiate HAART regimen CD4+ cell count &gt; = 250 cells/mm3 within 60 day prior study entry HIV1 RNA &gt; 400 copies/ml within 60 day prior study entry Serum HBV DNA &gt; = 1,000,000 copies/ml within 60 day prior study entry Positive serum hepatitis B surface antigen ( HbsAG ) Acceptable method contraception Pregnancy breastfeeding Allergy , sensitivity , intolerance study drug Alcohol consumption average 1 drink/day within past 30 day Decompensated cirrhosis HCV antibody positive know HCV RNA positive HDV antibody positive Certain medical condition Use certain medication antiHBV activity within 90 day study entry Use systemic corticosteroid within 30 day study entry Use systemic antineoplastic , immunomodulatory treatment , radiation within 24 week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Antiretroviral Therapy , Highly-Active</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>